{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:53:36Z","timestamp":1771876416407,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[1994,11,1]],"date-time":"1994-11-01T00:00:00Z","timestamp":783648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":9198,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1994,11]]},"DOI":"10.1093\/oxfordjournals.annonc.a059010","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T17:14:24Z","timestamp":1486142064000},"page":"817-820","source":"Crossref","is-referenced-by-count":64,"title":["Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease"],"prefix":"10.1016","volume":"5","author":[{"given":"L.","family":"Devizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bonfante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Balzarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valagussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0005","first-page":"364","article-title":"Outcome of patients with Hodgkin\u2019s disease relapsing after alternating MOPP\/ ABVD","volume":"12","author":"Bonfante","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2","key":"10.1093\/oxfordjournals.annonc.a059010_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin\u2019s disease after combination chemotherapy: The low probability of cure","volume":"10","author":"Longo","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/0277-5379(91)90208-U","article-title":"Salvage treatments in Hodgkin\u2019s disease","volume":"5","author":"Bonadonna","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.7326\/0003-4819-96-2-139","article-title":"Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin\u2019s disease","volume":"96","author":"Santoro","year":"1982","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a059010_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/annonc\/2.suppl_1.9","article-title":"Primary and salvage chemotherapy in advanced Hodgkin\u2019s disease: The Milan Cancer Institute experience","volume":"2","author":"Bonadonna","year":"1991","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a059010_bb0030","first-page":"23","article-title":"CCNU, etoposide and prednimustine (CEP) in refractory Hodgkin\u2019s disease","volume":"13","author":"Santoro","year":"1986","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0035","first-page":"1203","volume":"71","author":"Pfreundschuh","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1987.5.4.556","article-title":"MIME chemotherapy (methil-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin\u2019s disease","volume":"5","author":"Haghemeister","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0045","first-page":"475","article-title":"Third line chemotherapy for resistant Hodgkin\u2019s disease with lomustine, etoposide and methotrexate","volume":"71","author":"Tseng","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0050","first-page":"80","article-title":"Combination chemotherapy for the treatment of Hodgkin\u2019s disease in relapse","volume":"11","author":"Straus","year":"1983","journal-title":"Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin and vinblastine. Cancer Chemother Pharmacol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00000421-199104000-00004","article-title":"A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer","volume":"14","author":"Depierre","year":"1991","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1093\/oxfordjournals.annonc.a059010_bb0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous Vinorelbine in first line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/oxfordjournals.annonc.a059010_bb0065","first-page":"33","article-title":"Efficacy of navelbine in advanced breast cancer","volume":"16","author":"Canobbio","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0070","first-page":"1232","article-title":"Navelbine as second line chemotherapy in metastatic breast carcinoma (MBC): An ARTAC phase II trial","volume":"207","author":"Fumdeare","year":"1990","journal-title":"Proc Am Ass Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0075","series-title":"Navelbine Update and New Trends","first-page":"253","article-title":"Phase II study of vinorelbine (navelbine) in previously treated Hodgkin\u2019s disease and non Hodgkin\u2019s lymphoma","author":"Eghbali","year":"1991"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0080","series-title":"Essai de phase IX In; Navelbine actualit\u00e9s et perspectives","first-page":"267","article-title":"Etude clinique de l\u2019efficacit\u00e9 de la Navelbine dans la maladie de Hodgkin","author":"Benchekroun","year":"1990"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0085","first-page":"278","article-title":"Methil-Gag, ifosfamide, navelbine, etoposide (MINE) as salvage therapy for refractory or relapsed Hodgkin\u2019s disease (HD)","volume":"10","author":"Oberlin","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0090","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.1016\/S0021-9258(18)90830-6","article-title":"Contrasting effects of Tau and microtubule-associated protein 2 in the vinblastineinduced aggregation of tubulin","volume":"259","author":"Ludvena","year":"1984","journal-title":"J Bio Chem"},{"issue":"2","key":"10.1093\/oxfordjournals.annonc.a059010_bb0095","first-page":"9","article-title":"Biochemical effects of navelbine on tubulin and associated proteins","volume":"16","author":"Fellous","year":"1989","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1093\/oxfordjournals.annonc.a059010_bb0100","first-page":"21","article-title":"Pharmacokinetics and metabolism of navelbine","volume":"16","author":"Krikorian","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0105","first-page":"285","article-title":"Phase I pharmacologic study of a new vinca alkaloid: Navelbine","volume":"27","author":"Reizenstein","year":"1989","journal-title":"Cancer Lett"},{"key":"10.1093\/oxfordjournals.annonc.a059010_bb0110","first-page":"368","article-title":"Etoposide, vinblastine, and doxorubicin (EVA) as initial chemotherapy for patients with advanced Hodgkin\u2019s disease","volume":"13","author":"Shulman","year":"1994","journal-title":"ASCO Proceedings"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419632734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419632734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/5\/9\/817\/414469\/5-9-817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T12:20:21Z","timestamp":1658578821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419632734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,11]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1994,11]]}},"alternative-id":["S0923753419632734"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a059010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1994,11]]}}}